Vir Biotechnology, Inc. (VIR) |
|
9.37 0.16 (1.74%)
|
09-29 16:00 |
|
Open: |
9.3 |
Pre. Close: |
9.21 |
|
High:
|
9.49 |
Low:
|
9.292 |
|
Volume:
|
1,192,704 |
Market Cap:
|
1,258(M) |
|
|
|
Technical analysis |
as of: 2023-09-29 4:31:07 PM |
|
Short-term rate:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 13.54 One year: 15.49 |
| Support: |
Support1: 8.89 Support2: 7.4 |
| Resistance: |
Resistance1: 11.6 Resistance2: 13.27 |
| Pivot: |
9.64  |
| Moving Average: |
MA(5): 9.26  MA(20): 10.2
MA(100): 18.41 MA(250): 22.34 |
| MACD: |
MACD(12,26): -1.1 Signal(9): -1.2 |
| Stochastic oscillator: |
%K(14,3): 14.9 %D(3): 12.2 |
| RSI: |
RSI(14): 24.8 |
| 52-week: |
High: 31.54 Low: 8.89 |
| Average Vol(K): |
3-Month: 1,601 (K) 10-Days: 1,419 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ VIR ] has closed above bottom band by 35.4%. Bollinger Bands are 56.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
9.5 - 9.54 |
9.54 - 9.58 |
|
Low:
|
9.18 - 9.23 |
9.23 - 9.28 |
|
Close:
|
9.29 - 9.37 |
9.37 - 9.44 |
|
Company Description |
|
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California. |
Headline News |
Thu, 28 Sep 2023
Hepatitis-B-Virus Infection Pipeline and Clinical Trials Pipeline Analysis 2023 (Updated): 80+ Companies - Benzinga
Wed, 27 Sep 2023
2023-09-27 | NDAQ:VIR | Press Release | Vir Biotechnology Inc - Stockhouse Publishing
Wed, 27 Sep 2023
Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by Wedge ... - MarketBeat
Wed, 20 Sep 2023
HIV Vaccine Candidate Expects Early Data in 2024 — Precision ... - Precision Vaccinations
Wed, 20 Sep 2023
Vir Biotechnology Announces First Participant Dosed in New Phase ... - BioSpace
Wed, 06 Sep 2023
Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Acquired by ... - MarketBeat
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
134 (M) |
| Shares Float |
89 (M) |
|
% Held by Insiders
|
14.2 (%) |
|
% Held by Institutions
|
75.9 (%) |
|
Shares Short
|
4,570 (K) |
|
Shares Short P.Month
|
3,540 (K) |
Stock Financials |
|
EPS
|
-1.83 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
13.48 |
|
Profit Margin (%)
|
-53.4 |
|
Operating Margin (%)
|
-55.1 |
|
Return on Assets (ttm)
|
-7 |
|
Return on Equity (ttm)
|
-14 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
7.67 |
|
Sales Per Share
|
3.65 |
|
EBITDA (p.s.)
|
-1.91 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-362 (M) |
|
Levered Free Cash Flow
|
-365 (M) |
Stock Valuations |
|
PE Ratio
|
-5.15 |
|
PEG Ratio
|
-0.3 |
|
Price to Book value
|
0.69 |
|
Price to Sales
|
2.56 |
|
Price to Cash Flow
|
-3.48 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
